How many investments has Bios Partners made?

Bios Partners has 11 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.

What stage does Bios Partners invest at?

Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.

What sectors does Bios Partners focus on?

Bios Partners focuses on Biotech, Healthtech, Medical Devices.

Where is Bios Partners located?

Bios Partners is headquartered in Fort Worth, US.

Bios Partners

Venture capitaloperating company · company profile

Fort Worth · Seed–Growth · 16 people tracked

Also known as BIOS CAPITAL MANAGEMENT, LP · STEELHEAD CAPITAL MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Bios Partners

644 people in our graph share verified history with the Bios Partners team — schools, employers, funds. One of them is your warm intro.

Simon Woutersunlockedknows Giacomo Piccinini · together at KU Leuven (overlapped)

×2knows the team · via KU Leuven

×2knows the team · via Yale University School of Medicine

×2knows the team · via University of Illinois Chicago

knows the team · via UT Southwestern Medical Center

knows the team · via Texas Christian University

✨ Fox Verdict

Investment thesis

Bios Partners argues that scientific talent is distributed evenly across the country while venture capital concentrates on the coasts, particularly Silicon Valley and the Northeastern US. The firm seeks to disrupt this 'geographic favoritism' by investing in scientifically compelling opportunities in the Central US that are typically overlooked and undervalued. Its approach centers on company cultivation and is driven by science, drawing on a team with combined experience across hedge funds, private equity, clinical drug development, and public pharma/biotech analysis.

Invests inBiotech Healthtech Medical Devices Fort Worth United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Growth

Fort Worth, Texas, US

Instruments

Equity

Founded

2014

AUM

$202.5M

Tracked investments

IPOs

Team · 16 people

from the firm's website & curated & public directories

Leslie W. Kreis, Jr.· Managing Partner & Co-Founder

Has over 25 years of public and private equity investing experience, is Managing Principal at Steelhead Capital Management, and a founding member of Cowtown Angels. Previously a VP at HBK Investments managing a $3B global portfolio. BBA in Finance from TCU.

l•••@biospartners.comreveal

Aaron G.L. Fletcher· Managing Partner· Fort Worth, Texasin

Managing director of Bios Partners and founder/president of Bios Research, providing healthcare public equity research. Holds a PhD in biochemistry from Colorado State University and is a visiting professor at Dallas Baptist University with 10+ years in biotech/healthcare equity consulting.

a•••@biospartners.comreveal

Amanda de la Garza· Partner· Dallas, Texasin

Has over five years of financial and scientific analysis experience as an analyst at Bios Research and Bios Partners. Holds a BS in Biology and an MPH in epidemiology and global health, and is pursuing a PhD in Leadership Studies.

a•••@biospartners.comreveal

John Fucci· Partner· Fort Worth, Texasin

Partner at Bios Partners focused on diligence, negotiations, portfolio management, and investor relations. Serves on the board of Lantern Pharma and was previously a VP at Steelhead Capital Management. Double majored in Finance and Entrepreneurial Management at TCU.

j•••@biospartners.comreveal

Stella Robertson· Partner· Fort Worth, Texasin

Co-founder of Bios Partners with 25+ years in pharmaceutical R&D. Former VP of R&D at Alcon Laboratories overseeing the ophthalmic pipeline. Holds a PhD in biology-immunology from Johns Hopkins University and completed Harvard Business School's PMD.

s•••@biospartners.comreveal

Stephen Phillips· Vice President· Fort Worth, Texas, United Statesin

Vice President at Bios Partners focused on diligence, negotiations, portfolio management, and investor relations. Previously VP at Moorea Capital family office. Holds an MBA from Dallas Baptist University.

s•••@biospartners.comreveal

Tim Van Treuren· Principal· Fort Worth, Texasin

Joined Bios Partners in 2019, managing deal flow and leading scientific due diligence. Serves on the board of Bobcat Bio. Holds a PhD in Biomedical Sciences with an emphasis in Cancer Biology from UNT Health Science Center.

t•••@biospartners.comreveal

Tim Van Treuren, PhD· Companies Seeking Investment· Fort Worth, Texas, United Statesin

o•••@biospartners.comreveal

Troy Osborn· Investor Relations· Austin, Texas, United Statesin

CFO at Bios Partners since June 2019. Previously an auditor at KPMG specializing in private equity and hedge fund accounting. Holds a Master's in Accounting from Abilene Christian University.

i•••@biospartners.comreveal

Blake Pate· Analyst· Dallas, Texasin 𝕏

Vice President of Investments at Bios Partners since May 2019, focused on due diligence and deal flow, and also VP of Bios Research. Holds a BS in Biology and a Master of Science in Biotechnology from Johns Hopkins University, and is a Network Partner for 2048 Ventures.

b•••@biospartners.comreveal

Daniel Schwarz· COO and CFO

d•••@biospartners.comreveal

Don Short· Chief Financial Officer· Canadain

Head of Venture Equity and Chief Compliance Officer for InvestX Financial (Canada), overseeing the investment team's five-factor model for late-stage private companies. A CFA and registered portfolio manager with 30+ years of experience, previously CIO at Qwest Investment Fund Management.

Giacomo Piccinini· Vice President· Milan, Lombardy, Italyin

Giacomo Piccinini is an Investment Manager at Panakes Partners. Trained as a bioengineer, he has experience in venture capital, the life science sector, and the startup ecosystem, with a focus on healthcare innovation and life science.

g•••@panakes.itreveal

Patrick Browning· Vice President· Fort Worth, Texasin

Patrick Browning is an Executive Director and Banker at J.P. Morgan Private Bank, where he advises family offices, business owners, investment professionals, and ultra-high-net-worth families in the Fort Worth area. Drawing on prior experience at a single-family office and private capital firm, he addresses client needs including wealth structuring, liquidity management, and concentrated asset planning. He facilitates access to J.P. Morgan's Commercial Bank, Investment Bank, and related business lines.

Roni Meintjes· Analyst· Dallas, Texas

Steven Hood· Vice President· Fort Worth, Texasin

What they invest in

from 10 of 11 portfolio companies

Biotech ×8Healthtech ×6Medical Devices ×4AI & Machine Learning ×2Cloud Computing ×1Cybersecurity ×1Deep Tech ×1GovTech ×1

HQs:United States×10

Investments · 11 tracked

founders shown can be your intro path

By year:2025 · 1 2023 · 1 2022 · 2 2021 · 2 2020 · 1 2018 · 1 2015 · 19 dated

Actuate Therapeuticsactuatetherapeutics.com in 𝕏NASDAQ: ACTUSep 2015

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations.

BiotechFort Worth, US

Daniel Schmitt(President & Chief Executive Officer)Paul Lytle(Executive Officer)inAndrew Mazar(Executive Officer)

Board Todd Thomson(Director)inRoger Sawhney(Director)Jason Keyes(Director)

Board seat Aaron G.L. Fletcher Leslie W. Kreis, Jr.· per SEC Form D

Co-investorsIllinois Ventures Kairos Venture Investments, Llc Bios

Azitraazitrainc.comNYSE: AZTRSep 2020 · $17M

Azitra is a clinical-stage biopharmaceutical company developing genetically engineered bacteria and proteins for treating skin diseases through precision dermatology.

AI & Machine LearningBiotechHealthtechFarmington, US

Francisco D. Salva(President and Chief Executive Officer)Azim Munivar(Executive Officer, Director, Promoter)

Board seat Stella Robertson Travis Whitfill· per SEC Form D

Co-investorsConnecticut Innovations KdT Ventures Leaps by Bayer

Cue Biopharmacuebiopharma.comNASDAQ: CUENov 2022SEC filingmedium confidence

Cue Biopharma is a precision immunotherapy company developing engineered therapies targeting allergic and autoimmune diseases.

BiotechHealthtechMedical DevicesBoston, US

Daniel Baker(Executive Officer)Colin Sandercock(Executive Officer)Dominic Borie(Chief Medical Officer and Head of Research and Development)in Sumita Ray(Executive Officer)inMichael Meluzio(Executive Officer)inRodolfo Chaparro(Vice President, Head of Immunology)

Board seat Aaron G.L. Fletcher· per SEC Form D · $30M raise · filed Nov 2022

Trefoil Therapeuticstrefoiltherapeutics.com inApr 2025✓ verified

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.

BiotechHealthtechMedical DevicesSan Diego, US

David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in

Board Christy Shaffer(Director)inRalph Bradshaw(Director)

Board seat Stella Robertson· per SEC Form D

Co-investorsExSight Ventures Hatteras Venture Partners Solasta Ventures Access Biotechnology Correlation Ventures FemHealth Ventures +2 more

ONL Therapeuticsonltherapeutics.com inMar 2023✓ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in

Board Aaron Fletcher(Director)in

Co-investorsExSight Ventures Invest Michigan Novartis Venture Fund Visionary Ventures InFocus Capital Partners, LLC Johnson & Johnson Innovation – JJDC +3 more

410 Medical410medical.com in 𝕏Aug 2018SEC filingmedium confidence

410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.

HardwareHealthtechMedical DevicesDurham, US

Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)in

Board JEFF TERRELL(Director)inSTANLEY D. LYNALL(Director)FRED GOLDWATER(Director)in MAYANK TANEJA(Director)in

Board seat Travis Whitfill· per SEC Form D · $4M raise · filed Aug 2018

Co-investorsBallad Ventures CU Healthcare Innovation Fund Duke Capital Partners OSF Ventures Wolfpack Investor Network Hatteras Venture Partners

Lung Therapeuticslungtx.comMar 2022

BiotechAustin, US

James Brian Windsor(President and CEO)Steven Idell(Director)

Board Aaron Fletcher(Director)inJoseph Woelkers(Director)Robert Mills(Director)

Board seat Aaron G.L. Fletcher· per SEC Form D

Co-investorsUT Horizon Fund

Actuateactuate.ai in 𝕏

Actuate provides AI-based video analytics that turn existing IP cameras and NVRs into a security detection system, offering real-time alerts for threats such as intruders, loitering, guns, and crowds.

AI & Machine LearningCloud ComputingCybersecurityGovTechSaaS

Sonny Tai(Co-Founder)inKen Francis(CEO)in

Co-investorsBling Capital Dorm Room Gray Line Partners MetaProp MetaProp Ventures Scribble Ventures +3 more

Stream Biomedicalstreambiomedical.comDec 2021

Stream Biomedical is a clinical-stage biotechnology company developing LG3, a biologic derived from a natural repair protein intended to protect and restore the brain by activating its repair systems.

BiotechDeep TechHealthtechHouston, US

H. Davis Adkisson(Chief Scientific Officer)inChris Garabedian(Director)William Schwieterman(Board of Directors)Fred Callori(Director)

Board Amanda De La Garza(Director)in

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

BobcatBio Encore Vision

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 3

3 IPOs

Actuate TherapeuticsNASDAQ: ACTUAzitraNYSE: AZTRCue BiopharmaNASDAQ: CUE

Portfolio news

latest coverage across their companies

410 Medical has filed a notice of an exempt offering of securities to raise $12 Million in New Funding. - intelligence360

410 Medical · intelligence360.news · Aug 25, 2026

Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes

Actuate Therapeutics · stocktitan.net · Aug 14, 2026

Actuate Therapeutics posts Q2 loss, advances elraglusib | ACTU Quarterly Report (10-Q)

Actuate · stocktitan.net · Aug 14, 2026

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times

Cue Biopharma · manilatimes.net · Aug 14, 2026

/C O R R E C T I O N -- Azitra, Inc./ - AOL

Azitra · aol.com · Jul 15, 2026

News | Hatteras Venture Partners Healthcare Insights

Trefoil Therapeutics · hatterasvp.com · Jan 9, 2026

Frequently asked questions

How many investments has Bios Partners made?: Bios Partners has 11 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
What stage does Bios Partners invest at?: Bios Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What sectors does Bios Partners focus on?: Bios Partners focuses on Biotech, Healthtech, Medical Devices.
Where is Bios Partners located?: Bios Partners is headquartered in Fort Worth, US.

Similar investors

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M